Scholl Hendrik Peter Sells Shares of Belite Bio, Inc
Belite Bio's Chief Medical Officer sold shares worth $1.45 million.
Key Points
- Scholl Hendrik Peter, Chief Medical Officer of Belite Bio, sold 10,000 shares at $145.24 each on June 18, 2026, totaling $1.45 million.
- Belite Bio, Inc's stock was trading near $146.12 on Monday, with a market cap of approximately $5.86 billion.
- Mizuho maintained a 'buy' rating on Belite Bio with a $215 price target, reflecting strong analyst confidence.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Scholl Hendrik Peter, the Chief Medical Officer of Belite Bio, Inc, sold 10,000 shares of the company on June 18, 2026. The shares were sold at an average price of $145.24, totaling approximately $1.45 million. This transaction was not conducted under a pre-planned trading program.
Insider Buying and Selling at Belite Bio, Inc
In addition to Scholl's recent sale, Nathan Mata, Belite Bio's Chief Scientific Officer, also sold shares earlier in May. His transactions were part of a pre-planned trading program, with sales ranging from $153.21 to $155.64 per share.
Other Institutional Activity in Belite Bio, Inc
Several institutional investors have been adjusting their positions in Belite Bio. DARWIN GLOBAL MANAGEMENT, LTD. increased its stake by 29,708 shares, bringing its total to over 3.05 million shares valued at about $456.1 million. PARADIGM BIOCAPITAL ADVISORS LP initiated a new position with 1,114,784 shares worth approximately $177.7 million. UBS GROUP AG notably boosted its holdings by 639,607 shares, a 496.8% increase, to a total of 768,359 shares valued at around $122.5 million. Meanwhile, RTW INVESTMENTS, LP maintained its position with no change in shares, holding approximately 715,332 shares worth $114 million.
Belite Bio, Inc Stock Down 3.7%
Shares of NasdaqCM:BLTE traded near $146.12 on Monday. Belite Bio, Inc has a market cap of about $5.86 billion and a forward P/E ratio of 154.74. The stock's beta is -1.243, indicating it moves inversely to the market. Belite Bio's 52-week range spans from $56.10 to $200.00, with a 50-day moving average of $151.91 and a 200-day moving average of $138.36. The company holds a strong current ratio of 33.71, reflecting its robust liquidity position.
$BLTE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 26, 2026, Mizuho maintained its 'buy' rating on Belite Bio with a price target of $215. HC Wainwright & Co. reiterated a 'buy' rating with a $200 price target on May 21, 2026. Analysts generally view Belite Bio positively, with a consensus recommendation of 'strong buy' and an average price target of $210.50 based on eight analyst opinions.
About Belite Bio, Inc
Belite Bio, Inc is a biotechnology company based in San Diego, California. It focuses on developing novel therapeutics for unmet medical needs. The company's lead product, Tinlarebant, is in phase 3 trials for treating retinal diseases. Belite is also working on LBS-009, targeting liver diseases and type 2 diabetes. Dr. Yu-Hsin Lin leads the company as CEO, guiding its efforts in the healthcare sector.
Bottom Line
Belite Bio, Inc's recent insider sales and institutional activities are notable for investors tracking the company's performance. While insider transactions can be informative, they don't necessarily predict future stock movements. The data from these events is backward-looking, reflecting past actions and may not indicate current or future positions.
Get Belite Bio, Inc alerts
New 13F filings, insider trades, and analyst moves on $BLTE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.